recently proposed the use of circulating mRNA from GC-responsive genes, such as DSIPI, DDIT4, and FKBP5, as potential biomarkers in patients with autoimmune Addison’s disease; however, further research is needed to explore the potential and validity of transcriptional biomarkers for GC replacement therapy (41). This evidence concerns the gene FKBP5 and chronic primary adrenal insufficiency.